Sciences occultes

12 340 résultats

Trier parPrix croissant

Pertinence Auteur A - Z Auteur Z - A Titre A - Z Titre Z - A Prix croissant Prix décroissant Libraire A - Z Libraire Z - A

Par page25

25 50 100

Filtres

Sciences, Academy of NaturalBiblio.com

The Academy of Natural Sciences of Philadelphia Classic Reprint

National Academies of Sciences, Engineering, and MedicineBiblio.com

Regulatory Processes for Rare Disease Drugs in the United States and European Union: Flexibilities and Collaborative Opportunities

A9780309726559Paperback / softback. New. <p>Rare diseases such as sickle cell disease and thalassemia affect up to 30 million people in the United States and at least 300 million across the globe. Congress called on the U.S. Food and Drug Administration FDA to sponsor a National Academies study on processes for evaluating the safety and efficacy of drugs for rare diseases or conditions in the United States and the European Union. The resulting report provides recommendations for enhancing and promoting rare disease drug development by improving engagement with people affected by a rare disease advancing regulatory science and fostering collaboration between FDA and the European Medicines Agency.</p>Table of Contents<br /><ul><li>Front Matter</li><li>Summary</li><li>1 Introduction</li><li>2 FDA Flexibilities Authorities and Mechanisms</li><li>3 EMA Flexibilities Authorities and Mechanisms</li><li>4 Alternative and Confirmatory Data</li><li>5 FDA and EMA Collaboration</li><li>Appendix A: Biographical Sketches of Committee Members and Staff</li><li>Appendix B: Disclosures of Unavoidable Conflicts of Interest</li><li>Appendix C: Public Meeting Agendas</li><li>Appendix D: Centre for Innovation in Regulatory Science Data Analysis Methodology</li><li>Appendix E: Qualitative Interview Summary and Methodology</li><li>Appendix F: Non-Exhaustive List of Patient Focus Drug Development Meetings and Patient Listening Sessions for Rare Diseases Between 2013 and 2023</li><li>Appendix G: List of Orphan Approvals by FDA and EMA Between 2018 and 2022</li><li>Appendix H: Select Examples of Rare Disease Drug Products</li><li>Appendix I: FDA and EMA Resources Policies and Programs Relevant for Drug Development for Rare Diseases and Conditions</li></ul> paperback

The Saint Bookstore · Royaume-Uni39,39 £GB≈ 44,98 €